 |
1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea |
|---|---|
| Trade Name | |
| Orphan Indication | Gastrointestinal stromal tumours |
| EU Market Approval | EU |
| EU Designation Date | 2017-11-08 00:00:00 |
| Sponsor | Worldwide Clinical Trials Limited |
